Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Conmed (CNMD) over the last 16 years, with Q4 2025 value amounting to $82.1 million.

  • Conmed's Accumulated Expenses rose 2565.63% to $82.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $82.1 million, marking a year-over-year increase of 2565.63%. This contributed to the annual value of $82.1 million for FY2025, which is 2565.63% up from last year.
  • As of Q4 2025, Conmed's Accumulated Expenses stood at $82.1 million, which was up 2565.63% from $76.1 million recorded in Q3 2025.
  • In the past 5 years, Conmed's Accumulated Expenses ranged from a high of $82.1 million in Q4 2025 and a low of $40.9 million during Q1 2021
  • Its 5-year average for Accumulated Expenses is $58.0 million, with a median of $55.2 million in 2023.
  • Per our database at Business Quant, Conmed's Accumulated Expenses surged by 3359.4% in 2021 and then tumbled by 951.43% in 2022.
  • Conmed's Accumulated Expenses (Quarter) stood at $60.5 million in 2021, then fell by 9.51% to $54.7 million in 2022, then grew by 28.02% to $70.1 million in 2023, then fell by 6.71% to $65.4 million in 2024, then grew by 25.66% to $82.1 million in 2025.
  • Its Accumulated Expenses stands at $82.1 million for Q4 2025, versus $76.1 million for Q3 2025 and $67.9 million for Q2 2025.